DOCSLIB.ORG

In 'Ih E News

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In 'Ih E News •© 1992 Nature Publishing Group http://www.nature.com/naturebiotechnology IN 'IH E NEWS/ FDA USER FEES GAIN MOMENTUM •The U.S.FoodandDrugAdministra­ tion the company has received regard­ its rHB1.1 recombinant hemoglobin tion (FDA, Bethesda, MD) and the drug ing its research on cystic fibrosis; at the product. The trials were successful. industry are near an agreement regard­ beginning of this year, recombinant rHB1.1 is designed to replace blood lost ing user fees to speed up the drug ap­ cystic fibrosis transmembrane conduc­ in surgery. proval process. Under the plan, FDA tance regulator was also named an or­ •Celtrix (Santa Clara, CA) completed proposes that drug companies pay sev­ phan drug. phase II trials of its BetaKine for treat­ eral fees: $150,000 for each drug appli­ •Bio-Technology General (New York) ment of macular holes, wounds of the cation, regardless of whether it is in a received approval to market its recom­ retina in the macular region of the eye. life-saving category; $50,000 per com­ binant human growth hormone in Is­ Unless successfully repaired, macular pany per year; $5,000 for each product rael for treatment ofTurner' s syndrome, holes may diminish visual acuity, lead­ on the market. Generic drugs and medi­ a genetic disorder in which girls are ing to legal blindness. The trials had cal devices would not yet be included in born with only one healthy X chromo­ positive results. The company is collect­ the plan. In return for the fees, FDA some. ing data in preparation of phase III must cut the average time it takes to •Bristol-Myers Squibb (New York) studies. review new drug applications from the filed a new drug application (NDA) •Lynx Therapeutics (Foster City, CA) more than 20 months currently to 12 with FDA to market the anti-cancer drug is preparing an investigational new drug months, and cut the average time of taxol. The company is relinquishing (IND) application for its antisense com­ review on life-saving drugs to six months orphan drug designation for taxol, ap­ pound that targets the messenger RNA from the current one year. To accom­ parently to market the drug as treat­ coded by the p53 gene. The compound plish this, the agency will agree to hire ment for a wider variety of cancers. will be used to treat myelogenous leuke­ some 600 more specialists to do the •Cytogen (Princeton, NJ) started mia, and may later be applied to other scientific work necessary on new appli­ phase II trials of its OncoRad ovarian, types of cancer. cations for drugs and biological agents. the company's cancer therapeutic prod­ •Immunex (Seattle, WA) started phase This plan would be phased in over five uct. I trials of soluble tumor necrosis factor years, beginning in the 1993 fiscal year. •RMLMedicalLaboratories (Toronto, (TNF) receptor for the treatment of •Schering-Plough (Madison, NJ) re­ Canada) is expanding it~ phase II trials sepsis. The initial study will test the ceived FDA approval for its recombi­ ofVirulizin in the treatment of cancer. ability of soluble TNF receptor to block nant interferon alpha-2b for treatment The company also plans to pursue regu­ systemic inflammation caused by bacte­ of chronic hepatitis B, an infectious and latory approval to start trials in the U.S. rial infection. sometimes fatal liver disease. The drug and Europe. Current trials ofVirulizin •Isis Pharmaceuticals (Carlsbad, CA) is a copy of a naturally occurring pro­ are focused on recurrent and meta­ completed initial phase I trials for its tein that acts as an antiviral agent in the static melanoma, cancer of the pan­ antisense compound Isis 2105. The com­ body, and is already marketed for treat­ creas and kidney, and recurrent stom­ pound is designed to treat genital warts ment of hairy cell leukemia, AIDS-re­ ach, rectum, and colon cancer. caused by the human papilloma virus. lated Kaposi's sarcoma, genital warts, •CytRx (Norcross, GA) began a pilot •T Cell Sciences (Cambridge, MA) and hepatitis C. Although there are phase II trial with its TherMax gel, a and SmithKline Beecham (Philadelphia, vaccines to prevent hepatitis B, this drug topical therapeutic for pain, inflamma­ PA) filed an IND to begin trials ofsCR1 is the first treatment for the disease. tion, and healing associated with mild for treatment of adult respiratory dis­ •Genzyme (Cambridge,MA) received to moderate burns. tress syndrome (ARDS). The initial tri­ approval to market Ceredase in Israel. •ProCyte (Kirkland, WA) conducted als will be conducted in burn patients at Ceredase is an enzyme replacement a study in France with peptide copper to risk of developing ARDS; after burn therapyforpatientswith type I Gaucher halt hair loss in balding men. The study injury, fluid and white blood cells may disease. The drug was approved last was successful, and the company, as infiltrate the lungs and lead to pulmo­ year for use in the U.S., and applica­ soon as it receives financial backing for nary failure. tions are pending in the European Com­ the compound, expects to start clinical •AmylinPharmaceuticals (San Diego, munity, Canada, and other countries. testing. CA) began the first phase of clinical Also, Genzyme is starting phase 1/II •ImClone Systems (New York) is ex­ trials to test its synthetic amylin hor­ trials for Vianain enzymatic panding pilot studies of its anti-cancer mone therapy for diabetes. Drugs the debridement agent. Studies so far have vaccine, MelVax, for treatment of ma­ company hopes to develop would re­ indicated that Vianain appears to be lignant melanoma. The new patient place amylin in young diabetics who rapid and effective in removing non­ group will receive MelVax and an adju­ have difficulties with insulin therapy viable tissue from burn sites. vant intended to boost immune re­ and where amylin appears to be defi­ Genzyme received orphan drug desig­ sponse against melanoma tumor cells. cient, and block the action of the hor­ nation for its cystic fibrosis gene therapy. •Somatogen (Boulder, CO) has com­ mone in older patients with adult onset This is the second orphan drug designa- pleted the first stage of phase I trials of diabetes where there is an excess of the 940 BID/TECHNOLOGY VOL 10 SEPTEMBER 1992 •© 1992 Nature Publishing Group http://www.nature.com/naturebiotechnology hormone. Phase I trials are aimed at each other's patents and patent appli­ addressing a treatment for the young. cations related to anti-endotoxin MAbs. Centocor also formed a strategic alli­ AIDS CONFERENCE ance with Eli Lilly (Indianapolis, IN) •Biocine (Emeryville, CA) reported that gives Centocor at least $1 00 million that 12 vaccinated subjects who received and will give Lilly a 5 percent stake in 3 immunizations with the vaccine for­ Centocor. Lilly acquires marketing mula of recombinant gp120 plus adju­ rights to Centocor'sHA-lA, as well as an vant produced neutralizing antibodies option to spend additional money for against HIV. rights to Centocor's MAb platelet ag­ •Genentech's (S. San Francisco, CA) gregation inhibitor, CentoRx. gp120 vaccine was given to 28 HIV­ •Immunex and Hoechst (Frankfurt, negative adult volunteers. Two weeks Germany) agreed to settle all contract after the third immunization, 7 of 10 and other claims in two lawsuits pend­ subjects who had been given 300 meg ing between them. The suits dealt with doses developed fusion inhibition anti­ granulocyte macrophage colony-stimu­ body, and neutralization antibody was lating factor-a drug Immunex manu­ found in 9 of l 0 subjects to the homolo­ factures that is used in autologous bone gous isolate IIIB. marrow transplants-and give •ImmunoAG's (Wien,Austria) vaccine, Immunex exclusive rights to the drug recombinantgpl60, stimulated HIV anti­ in the U.S., while giving Behringwerke bodies and was well tolerated in 60 HIV­ (Marburg, Germany), a subsidiary of negativevolunteers. Hoechst, significantly increased royal­ •Immune Response (San Diego, CA) ties. andRhone-Poulenc Rorer (Collegeville, •Pharmaceutical Proteins (Edinburgh, PA) presented the results of a dose­ U.K.) and Wyeth-Ayerst (Philadelphia, ranging study of their HIV immuno­ PA) have entered into a long-term col­ therapeutic. The study demonstrated laboration to develop special use products that the HIV immunotherapeutic sig­ for metabolic, geriatric, and pediatric ap­ nificantly stimulated antibody and cel­ plications. The products will utilize the lular immune responses in treated pa­ technology ofproduction ofprot eins in tients. the milk of transgenic animals. •Tanox Biosystems (Houston, TX), • British Bio-technology (BBT, Oxford, University Hospital of Ziirich (Switzer­ U.K.) and Glaxo (New York) agreed to • V~ral Antigens • V1ral 0 A • Pur1f1ed land), and Ciba-Geigy (Basel, Switzer­ jointly develop BB-882, BBT's anti-in­ Protems • Human AB Serum • aturalll 2 land) completed a study of a mono­ flammatory drug. The companies will • V1rus Isolation • V1ral 0 A Amphf1cauon clonal antibody against HIV. Antibody collaborate primarily on the use of the Pr1mers • V1ral 0 A Controls For PCR therapy aims at controlling HIVby pro­ drug in the treatment of asthma. BBT • Macrophage Cultures • Elu nated Human viding an infected person with antibod­ started phase I trials of the drug, and lymphocytes • Adult Fresh Cultured ies that can neutralize or block the Glaxo is funding the trials. Glaxo will Mononuclear Cells • Elutnated Human also fund phase II trials. virus. The results of the limited study Monocytes • Cultured Cord Blood seem to show the antibody was well •Oxford Glycosystems (Abingdon, tolerated by the volunteer AIDS pa­ U.K.) and SmithKline Beecham (Ep­ Mononuclear Cells • Electron Microscopy tients. som, U.K.) signed a research agree­ • Fresh Cultured PHA-st1mulated •Genelahs Technologies (Redwood ment focused on developing carbohy­ Mononuclear Cells • Fresh Heparimzed City, CA) presented results of the phase drate-based inhibitors of selectin-medi­ Cord Blood • PHA·s!lmulated Cord Blood 1B study of its anti-AIDS drug, GLQ223, ated cell adhesion.
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • Power List 2018
    APRIL 2018 # 40 Editorial Upfront In My View Sitting Down With Stop and look at how far Preparing for the EU’s new What can algae teach us Sophie Kornowski-Bonnet, the industry has come data protection regulation about medicine design? Roche Partnering 09 10 – 11 20 – 21 50 – 51 100 Power List 2018 www.themedicinemaker.com Continuous Growth Fibra-Cel® disks—3-D growth matrix for perfusion and continuous processes Suspend your disbelief: > Less susceptible to shear forces, The three-dimensional Fibra-Cel matrix clogging, and fouling entraps anchorage dependent and > Ideal for secreted product and vaccine suspension cells—for optimized growth production conditions and increased yields. > Suitable for GMP production > For use in autoclavable, sterilize-in- place or BioBLU® Single-Use Vessels www.eppendorf.com/Fibra-Cel Fibra-Cel® is a registered trademark owned by Imerys Minerals California, Inc., USA and licensed to Eppendorf, Inc., USA. Eppendorf®, the Eppendorf Brand Design and BioBLU® are registered trademarks of Eppendorf AG, Germany. All rights reserved, including graphics and images. Copyright © 2018 by Eppendorf AG. tmm_epp_ad_210x266_2018_04.indd 1 28.03.18 13:34 Online this Month The Power List The 2018 Power List, starting on page 24 of this issue, features 100 of the most inspirational professionals involved in A Scientist Walks into a Bar... format to the public”. Generally, drug development. The list was compiled it involves scientists speaking on a based on reader nominations and And gives a presentation as part variety of topics, from medicine, to feedback from a judging panel – but any of Pint of Science, a global science neuroscience, to robotics and more, in list will always be subjective.
    [Show full text]
  • List of Section 13F Securities
    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
    [Show full text]
  • A Balanced Trade Context for HIV Patent Pool
    iMedPub Journals 2011 TRANSLATIONAL BIOMEDICINE Vol. 2 No. 1:3 This article is available from: http://www.transbiomedicine.com doi: 10:3823/420 A Balanced Trade Context for HIV Patent Pool Daniele Dionisio, M.D. Member, European Parliament Working Group on Innovation, Access to Medicines and Poverty- Related Diseases. Reference Advisor for “Drugs for the developing countries”, SIMIT (Italian Abstract Society for Infectious and Tropical Diseases). Former Director, Infectious Disease Division, Pistoia city Hospital (Italy). Background: Reluctance of the multinational pharmaceutical companies to join the Medicines Patent Pool plan for HIV drugs (antiretrovirals-ARVs) might undermine E-mail: [email protected] its desirable objective of scaling up long-term, extended access to novel, affordable and appropriate ARV formulations in resource-limited settings. Methods: This paper makes an analysis of conflicting issues and calls for a trade context facilitating a reverse of multinational drug manufacturers’ reluctance to join patent pool. To this aim, partnerships between multinational companies are urged first to make cutting edge brand fixed-dose combination (FDC) ARVs promptly avail- able, and secondly, to allow patent pool agreements to be negotiated immediately afterwards. This context rejects clauses that exclude middle-income countries from sharing in the patent pool. Expected results: The suggested trade context can help speed up the partici- pation of originator pharmaceutical companies in the Medicines Patent Pool, while allowing them to maintain competitiveness, take advantage of incoming joint ven- ture opportunities and circumvent the need for additional incentives. This context potentially tackles in an appropriate way the directions of evolution in emerging markets, while bringing benefits to resource-limited populations, multinational drug corporations and manufacturers from middle-income countries.
    [Show full text]
  • Lilly to Acquire Imclone Systems in $6.5 Billion Transaction
    Lilly to Acquire ImClone Systems in $6.5 Billion Transaction Creates a Global Leader in Oncology Biopharmaceuticals Boosts Oncology Pipeline With Up to Three Promising Targeted Therapies in Phase III in 2009 INDIANAPOLIS and NEW YORK, Oct 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Inc. (Nasdaq: IMCL) today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion. The offer represents a premium of 51 percent to ImClone's closing stock price on July 30, 2008, the day before an acquisition offer for ImClone was made public. ImClone's board recommends that ImClone's shareholders tender their shares in the tender offer. Additionally, certain entities associated with ImClone's chairman, Carl C. Icahn, holding approximately 14 percent of ImClone's outstanding common stock, have agreed to tender their shares in the tender offer. This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry, offering both targeted therapies and oncolytic agents along with a pipeline spanning all phases of clinical development. The combined oncology portfolio will target a broader array of solid tumor types including lung, breast, ovarian, colorectal, head and neck, and pancreatic, positioning Lilly to pursue treatments of multiple cancers. Combining with ImClone will further strengthen Lilly's growing portfolio of first-in-class and best-in-class pharmaceutical products, enabling Lilly to better support oncologists, with the ultimate goal of delivering better outcomes for cancer patients.
    [Show full text]
  • The Path Less Costly
    COMMENtaRY CASE STUDY The path less costly Brady Huggett When faced with a competitive threat, two companies took diametrically opposite approaches. Both were ultimately successful, but Genzyme’s decision proved to be the cleaner and cheaper option. s the world’s leader in developing enzyme-replacement drugs, and Novartis of Basel. Houston-based Tanox was founded in 1986 to AGenzyme has always understood the importance of first to market. In focus on anti-IgE antibodies and by 1989 was looking for a clinical 1991, the company obtained approval for Ceredase (alglucerase injection), development partner; it sent samples of its candidate to both Genentech an enzyme replacement therapy for lysosomal storage disease (LSD) type and Ciba Geigy (the company that would later become Novartis). 1 Gaucher. Three years later, its second-generation product, Cerezyme Genentech passed. Ciba Geigy, however, began working with Tanox (imiglucerase for injection), was also cleared for commercialization. The on anti-IgE antibodies for allergic diseases. lack of treatments for lysosomal storage diseases and effective patient out- Yet Genentech clearly had interest in the area, because it began its own reach and marketing meant that Genzyme could command soaring prices anti-IgE program a few years later—a move that prompted a misappro- for its orphan treatments. In 2000, the two drugs alone provided 66% of priation suit from Tanox. The companies fought in court for three years Genzyme’s entire product revenue. before Genentech, Tanox and Novartis reached a settlement and entered At this time, Novazyme Pharmaceuticals was a young company devel- a cross-licensing agreement for anti-IgE antibodies.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Active Labelers Run Date : Feb 19, 2018
    Active Labelers Run Date : Feb 19, 2018 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 01/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 01/01/1991 01/01/3000 00004 HOFFMANN-LA ROCHE 01/01/1991 01/01/3000 00006 MERCK & CO., INC. 01/01/1991 01/01/3000 00007 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00008 WYETH LABORATORIES 01/01/1991 01/01/3000 00009 PFIZER, INC 01/01/1991 01/01/3000 00013 PFIZER, INC. 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 01/01/3000 00023 ALLERGAN INC 01/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00025 PFIZER, INC. 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00029 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00032 ABBVIE INC. 01/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00046 AYERST LABORATORIES 01/01/1991 01/01/3000 00049 PFIZER, INC 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 ORGANON USA INC. 01/01/1991 01/01/3000 00053 CSL BEHRING LLC 01/01/1991 01/01/3000 00054 WEST-WARD PHARMACEUTICALS CORP. 01/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 01/01/1991 01/01/3000 00062 ORTHO MCNEIL PHARMACEUTICALS 01/01/1991 01/01/3000 00064 HEALTHPOINT, LTD.
    [Show full text]
  • Boot Camp Roster Through July 2015
    Participants in our GMP Boot Camps have come from these companies AB Biotechnologies Irisys, Inc. Abbott Vascular IVX Animal Health Acacia Biomedical Pte Ltd. J & J Packaging Actavis Pharmaceuticals Johnson Matthey Adhesives Research Karl Storz Endovision AHC Products, Inc. Kenco Management Services Alcon Labs King Pharmaceuticals Alk-Abello Source Materials Kleen Test Products Allergan, Inc. Kosan Amax Nutrasource KV Pharmaceutical American Red Cross La Jolla Pharmaceuticals Aptalis Pharmaceuticals Label World Artes Medical Labortorios Sophia Astellas Pharma Technologies Leica Microsystems Astra Zeneca Mayo Clinic Atex Technologies, Inc. Medicomp Inc. Auer Precision Co. Merck Avail Medical Metor-Logics Avema Pharma Solutions NBTY B. Braun Medical Nexgen Pharma BASF Nitto Denko Technical Inc. Baxa Corp. Norwich Pharmaceuticals Baxter Healthcare Novartis Animal Health US, Inc. Bayer Nuskin Enterprises Beckman Coulter Nutri-Mack Beiersdorf Inc. NuWorld Beauty Bend Research Oakley Biovail Ohm Laboratories Block Medical Organogenesis Inc. Boston Scientific Pacira Pharmaceuticals Bradley Corp. Palm Beach Pharmaceuticals Bristol-Myers Squibb Par Pharmaceutical Inc. CAMAG Pennakem LLC Carl Zeiss Meditec, Inc. Peter Cremer North America Cepheid Pfizer Church & Dwight Co. Philip Morris USA Cornerstone Research and Development Philliips Medisize GMP Training Systems, Inc. P.O. Box 2585 Orange, CA 92859 714-289-1233 www.GMPTrainingSystems.com Participants in our GMP Boot Camps have come from these companies CR Bard PL Developments Daiichi Sankyo Pharma Development Protab Laboratories Danisco USA Purdue Pharmaceuticals Dial Eisai Qm5 DSI, Inc. Ranbaxy Labs DSM Pharmaceuticals Raptor Pharmaceuticals Earthwise Nutritionals Regeneron Pharmaceuticals Edwards Lifesciences RJ Reynolds Co. Elan Robinson Pharma Co. Endosonics Romark Labs Eurand, Inc. Rosendin Electric Flextronics, Inc. Sanofi aventis FMI Schick, division of Energizer Forest Labs Sensible Organics Foster Corporation Shire Pharmaceuticals Garmon Corp.
    [Show full text]
  • Genentech 2002 Annual Report the Acceleration of Scientific Knowledge Over Time Has Been Profound— and It Is Ceaseless
    What we don’t yet know could change everything. Genentech 2002 Annual Report The acceleration of scientific knowledge over time has been profound— and it is ceaseless. Today, the span of time between great discoveries in medicine gets smaller and smaller due in part to the relatively new field of biotechnology. And the number of breakthroughs and new approaches to disease continues to grow. At Genentech, we believe we have only just begun to scratch the surface of biotechnology’s potential. Without a doubt, future discoveries will dramatically change our understanding of serious illnesses and potential treatments. Even more importantly, science is likely to create dramatic change at a more personal level— increasing the length and quality of life for our loved ones and ourselves. What if one day everyone could survive cancer? Cancer is the second leading cause of death in the United States behind heart disease, with over 1.2 million new cases diagnosed per year. Some predict it will become number one in the next 10 years. Curing cancer is our ultimate goal, but if we are able to keep cancer in check, extend patients’ lives and improve their quality of life, that will be a major victory over the disease. Genentech developed the first two therapeutic antibodies for cancer in the United States, Rituxan® (Rituximab), which was co-developed with IDEC Pharmaceuticals, and Herceptin® (Trastuzumab) — both of which attack malignant cells without causing extensive damage to healthy tissues. Rituxan and Herceptin are different from chemotherapy in that, although they are serious medicines, they tend to have relatively few side effects and can sometimes be taken for prolonged periods to stave off the disease.
    [Show full text]
  • 05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 05/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 04:25:50 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 07/01/2016 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 55513 AMGEN USA 00074 ABBOTT LABORATORIES 58406 AMGEN/IMMUNEX 68817 ABRAXIS BIOSCIENCE, LLC 53746 AMNEAL PHARMACEUTICALS 16729 ACCORD HEALTHCARE INCORPORATED 65162 AMNEAL PHARMACEUTICALS LLC 42192 ACELLA PHARMACEUTICALS, LLC 69238 AMNEAL PHARMACEUTICALS, LLC 10144 ACORDA THERAPEUTICS, INC. 53150 AMNEAL-AGILA, LLC 00472 ACTAVIS 00548 AMPHASTAR PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 69918 AMRING PHARMACEUTICALS, INC. 45963 ACTAVIS INC. 66780 AMYLIN PHARMACEUTICALS, INC. 46987 ACTAVIS KADIAN LLC 55724 ANACOR PHARMACEUTICALS 49687 ACTAVIS KADIAN LLC 10370 ANCHEN PHARMACEUTICALS, INC. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 43595 ANGELINI PHARMA, INC. 61874 ACTAVIS PHARMA, INC. 62559 ANIP ACQUISITION COMPANY 67767 ACTAVIS SOUTH ATLANTIC 54436 ANTARES PHARMA, INC. 66215 ACTELION PHARMACEUTICALS U.S., INC. 52609 APO-PHARMA USA, INC. 52244 ACTIENT PHARMACEUTICALS 60505 APOTEX CORP. 75989 ACTON PHARMACEUTICALS 63323 APP PHARMACEUTICALS, LLC. 69547 ADAPT PHARMA INC. 43485 APRECIA PHARMACEUTICALS COMPANY 76431 AEGERION PHARMACEUTICALS, INC. 42865 APTALIS PHARMA US, INC 50102 AFAXYS, INC. 58914 APTALIS PHARMA US, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 13310 AR SCIENTIFIC, INC. 27241 AJANTA PHARMA LIMITED 08221 ARBOR PHARM IRELAND LIMITED 17478 AKORN INC 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 24090 AKRIMAX PHARMACEUTICALS LLC 24338 ARBOR PHARMACEUTICALS, INC. 68220 ALAVEN PHARMACEUTICAL, LLC 59923 AREVA PHARMACEUTICALS 00065 ALCON LABORATORIES, INC. 76189 ARIAD PHARMACEUTICALS, INC. 00998 ALCON LABORATORIES, INC. 24486 ARISTOS PHARMACEUTICALS, INC.
    [Show full text]
  • Taking the Pulse of Biotech
    A Conversation with Nancy Chang OnTheRecord Taking the Pulse of Biotech Biotechnology is risky business. For every start-up that succeeds, between 15 and 20 fail. for HIV, just to prepare the materials alone cost $50,000 per patient, not counting our Houston Branch board member Nancy Chang beat the odds with Tanox Inc., a 20-year-old costs or our time. biotech company that has agreed to be acquired by industry behemoth Genentech Inc. When Tanox first started, I put every- thing I had into the company. We didn’t pay ourselves salaries; the company’s first tele- Q: With such a high failure rate, are biotechs phone system was built on borrowed mon- at risk of extinction? ey. But we did what we had to do to make progress, to grow the company, and these A: Just the opposite. Pharmaceutical compa- were gutsy, risky moves. nies are realizing that it’s so expensive to discover new drugs that they’re relying more Q: How has globalization changed the and more on biotechs for the discovery, de- pharmaceutical industry? velopment and concept phases. Look at it as Big Pharma relying on the little guy. This A: Every biotech company that starts out to- way, they don’t have to pay for the failures. day is global by necessity. You have to learn Eventually, they partner with the smaller how to do business all over the world, to do biotechs that do pass muster. research and development work outside the U.S., to have partnerships with international Q: You came to the U.S.
    [Show full text]